<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
                      "http://www.w3.org/TR/REC-html40/loose.dtd">
<HTML>
<HEAD>
<TITLE>extropians: Re: Drugs and Despair</TITLE>
<META NAME="Author" CONTENT="Anders Sandberg (asa@nada.kth.se)">
<META NAME="Subject" CONTENT="Re: Drugs and Despair">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000">
<H1>Re: Drugs and Despair</H1>
<!-- received="Sat May 20 04:04:25 2000" -->
<!-- isoreceived="20000520100425" -->
<!-- sent="20 May 2000 12:04:51 +0200" -->
<!-- isosent="20000520100451" -->
<!-- name="Anders Sandberg" -->
<!-- email="asa@nada.kth.se" -->
<!-- subject="Re: Drugs and Despair" -->
<!-- id="b49em6xo7uk.fsf@sans04.nada.kth.se" -->
<!-- inreplyto="19 May 2000 15:16:45 +0200&quot;" -->
<STRONG>From:</STRONG> Anders Sandberg (<A HREF="mailto:asa@nada.kth.se?Subject=Re:%20Drugs%20and%20Despair&In-Reply-To=&lt;b49em6xo7uk.fsf@sans04.nada.kth.se&gt;"><EM>asa@nada.kth.se</EM></A>)<BR>
<STRONG>Date:</STRONG> Sat May 20 2000 - 04:04:51 MDT
<P>
<!-- next="start" -->
<UL>
<LI><STRONG>Next message:</STRONG> <A HREF="3415.html">Steve: "Re: Can I kill  the &quot;semantics&quot;?"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="3413.html">Eugene Leitl: "Re: A new level of sophistication in cyber security"</A>
<!-- nextthread="start" -->
<LI><STRONG>Next in thread:</STRONG> <A HREF="3459.html">Anders Sandberg: "Re: Drugs and Despair"</A>
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#3414">[ date ]</A>
<A HREF="index.html#3414">[ thread ]</A>
<A HREF="subject.html#3414">[ subject ]</A>
<A HREF="author.html#3414">[ author ]</A>
</UL>
<HR NOSHADE><P>
<!-- body="start" -->
<P>
Just a paper I became aware of that relates to this thread, showing
<BR>
that cognitive psychotherapy and antidepressants have better effect
<BR>
together than isolated:
<BR>
<P><A HREF="http://www.nejm.org/content/2000/0342/0020/1462.asp">http://www.nejm.org/content/2000/0342/0020/1462.asp</A>
<BR>
<P>The New England Journal of Medicine -- May 18, 2000 -- Vol. 342, No. 20 
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<BR>
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System
<BR>
of Psychotherapy, and Their Combination for the Treatment of Chronic
<BR>
Depression
<BR>
<P>Martin B. Keller, James P. McCullough, Daniel N. Klein, Bruce Arnow,
<BR>
David L. Dunner, Alan J. Gelenberg, John C. Markowitz, Charles B.
<BR>
Nemeroff, James M. Russell, Michael E. Thase, Madhukar H. Trivedi,
<BR>
John Zajecka, Janice A. Blalock, Francis E. Borian, Charles
<BR>
DeBattista, Jan Fawcett, Robert M.A. Hirschfeld, Darlene N. Jody,
<BR>
Gabor Keitner, James H. Kocsis, Lorrin M. Koran, Susan G. Kornstein,
<BR>
Rachel Manber, Ivan Miller, Philip T. Ninan, Barbara Rothbaum, A. John
<BR>
Rush, Alan F. Schatzberg, Dina Vivian
<BR>
<P>Abstract
<BR>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Background. Patients with chronic forms of major depression
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are difficult to treat, and the relative efficacy of
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;medications and psychotherapy is uncertain.
<BR>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Methods. We randomly assigned 681 adults with a chronic
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nonpsychotic major depressive disorder to 12 weeks of
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;outpatient treatment with nefazodone (maximal dose, 600 mg
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per day), the cognitive behavioral-analysis system of
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;psychotherapy (16 to 20 sessions), or both. At base line,
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all patients had scores of at least 20 on the 24-item
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hamilton Rating Scale for Depression (indicating clinically
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;significant depression). Remission was defined as a score of
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 or less at weeks 10 and 12. For patients who did not have
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;remission, a satisfactory response was defined as a
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reduction in the score by at least 50 percent from base line
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and a score of 15 or less. Raters were unaware of the
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;patients' treatment assignments.
<BR>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results. Of the 681 patients, 662 attended at least one
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;treatment session and were included in the analysis of
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;response. The overall rate of response (both remission and
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;satisfactory response) was 48 percent in both the nefazodone
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;group and the psychotherapy group, as compared with 73
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percent in the combined-treatment group (P&lt;0.001 for both
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;comparisons).  Among the 519 subjects who completed the
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;study, the rates of response were 55 percent in the
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nefazodone group and 52 percent in the psychotherapy group,
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as compared with 85 percent in the combined-treatment group
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P&lt;0.001 for both comparisons). The rates of withdrawal were
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;similar in the three groups. Adverse events in the
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nefazodone group were consistent with the known side effects
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the drug (e.g., headache, somnolence, dry mouth, nausea,
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and dizziness).
<BR>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conclusions. Although about half of patients with chronic
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;forms of major depression have a response to short-term
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;treatment with either nefazodone or a cognitive
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;behavioral-analysis system of psychotherapy, the combination
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the two is significantly more efficacious than either
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;treatment alone. (N Engl J Med 2000;342:1462-70.)
<BR>
<P>See also the editorial:
<BR>
<A HREF="http://www.nejm.org/content/2000/0342/0020/1518.asp">http://www.nejm.org/content/2000/0342/0020/1518.asp</A>
<BR>
<P><PRE>
-- 
-----------------------------------------------------------------------
Anders Sandberg                                      Towards Ascension!
<A HREF="mailto:asa@nada.kth.se?Subject=Re:%20Drugs%20and%20Despair&In-Reply-To=&lt;b49em6xo7uk.fsf@sans04.nada.kth.se&gt;">asa@nada.kth.se</A>                            <A HREF="http://www.nada.kth.se/~asa/">http://www.nada.kth.se/~asa/</A>
GCS/M/S/O d++ -p+ c++++ !l u+ e++ m++ s+/+ n--- h+/* f+ g+ w++ t+ r+ !y
</PRE>
<P><!-- body="end" -->
<HR NOSHADE>
<UL>
<!-- next="start" -->
<LI><STRONG>Next message:</STRONG> <A HREF="3415.html">Steve: "Re: Can I kill  the &quot;semantics&quot;?"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="3413.html">Eugene Leitl: "Re: A new level of sophistication in cyber security"</A>
<!-- nextthread="start" -->
<LI><STRONG>Next in thread:</STRONG> <A HREF="3459.html">Anders Sandberg: "Re: Drugs and Despair"</A>
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#3414">[ date ]</A>
<A HREF="index.html#3414">[ thread ]</A>
<A HREF="subject.html#3414">[ subject ]</A>
<A HREF="author.html#3414">[ author ]</A>
</UL>
<!-- trailer="footer" -->
<HR NOSHADE>
<P>
<SMALL>
<EM>
This archive was generated by <A HREF="http://www.hypermail.org/">hypermail 2b29</A> 
: <EM>Thu Jul 27 2000 - 14:11:26 MDT</EM>
</EM>
</SMALL>
</BODY>
</HTML>
